ANVS

Annovis Bio, Inc. (ANVS) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Annovis Bio is a late-stage clinical biopharmaceutical company developing buntanetap, an oral small molecule designed to treat neurodegenerative diseases, specifically Alzheimer's disease (AD) and Parkinson's disease (PD). The company is currently conducting a pivotal Phase 3 study in early AD and an open-label extension study in PD. As of the filing date, the company has not generated substantial revenue and has not achieved profitable operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses rose to $18.01 million from $6.28 million year-over-year. This $11.73 million increase was driven primarily by a $11.9 million increase in costs for the AD 6-month trial and a $2.2 million increase for the PD open-label extension trial.
• Research and Development (R&D): R&D expenses surged to $16.72 million from $5.01 million, reflecting the ramp-up of clinical trial activities.
• Warrant Liability Fair Value: The company recorded a gain of $0.27 million from the change in fair value of warrant liabilities, compared to a $0.56 million gain in the prior year. The warrant liability balance decreased from $0.60 million to $0.33 million.
• Equity Issuances: During Q1 2026, the company issued 1.34 million shares under its Equity Distribution Agreement (ATM), raising net proceeds of approximately $3.70 million. This contrasts with Q1 2025, which included proceeds from a registered direct offering and ATM sales totaling nearly $19.8 million.
• Liquidity Position: Cash balances decreased by $5.31 million during the quarter due to operating burn, despite financing inflows.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for one year following the filing date. The company states its existing cash of $14.2 million is insufficient to fund operations for the next 12 months.
• Capital Requirements: The company expects to incur losses for the foreseeable future and will need to raise substantial additional capital to complete clinical development and commercialization. Plans include equity financings, debt, or deferring operating expenses.
• Clinical Progress:
  • Phase 3 AD Trial: Screening is expected to conclude on May 15, 2026, with full enrollment anticipated two months later.
  • PD Open-Label Extension: Initiated in January 2026, aiming to enroll 500 patients.
  • PDD Study: Protocol refinement is ongoing, contingent on additional funding.
• Subsequent Events:
  • Between April 9 and May 13, 2026, the company sold 0.8 million shares via ATM for net proceeds of $1.8 million.
  • On April 9, 2026, the company completed an underwritten public offering of 5.3 million units (stock + warrants) at $1.90 per unit, resulting in gross proceeds of $10.0 million and net proceeds of $9.3 million.
• Risks: Key risks include the inability to raise additional capital on acceptable terms, potential delays in clinical trials, and the uncertainty of regulatory approval for buntanetap.

Investor Verification Checklist

• Verify the sufficiency of the $9.3 million net proceeds from the April 2026 offering to extend the company's cash runway beyond the current "substantial doubt" threshold.
• Monitor the enrollment status of the pivotal Phase 3 AD trial, specifically the May 15, 2026 screening completion target.
• Review the terms of the new "Canaccord 2026 Warrants" issued in April 2026 (exercise price $2.50, 5.5-year term) for potential dilution impact.
• Assess the company's ability to secure funding for the proposed Parkinson's Disease Dementia (PDD) study, which is currently contingent on capital availability.
• Track the burn rate relative to the $14.2 million cash balance as of March 31, 2026, to gauge the urgency of future capital raises.